<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>6(8)</volume><submitter>Xiao C</submitter><pubmed_abstract>&lt;h4>Importance&lt;/h4>Loss of a previously effective response while still using adequate antidepressant treatment occurs in a relatively high proportion of patients with major depressive disorder (MDD); therefore, there is a need to develop novel effective treatment strategies.&lt;h4>Objective&lt;/h4>To assess the efficacy and safety of a single subanesthetic dose of esketamine in boosting the efficacy of oral antidepressants for treating fluctuating antidepressant response in MDD.&lt;h4>Design, setting, and participants&lt;/h4>This single-center, double-blind, midazolam-controlled pilot randomized clinical trial was conducted at Beijing Anding Hospital, Capital Medical University in China. The study enrolled participants aged 18 years and older with fluctuating antidepressant response, defined as patien</pubmed_abstract><journal>JAMA network open</journal><pagination>e2328817</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10425830</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Esketamine vs Midazolam in Boosting the Efficacy of Oral Antidepressants for Major Depressive Disorder: A Pilot Randomized Clinical Trial.</pubmed_title><pmcid>PMC10425830</pmcid><pubmed_authors>Zheng Y</pubmed_authors><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Hu Y</pubmed_authors><pubmed_authors>Deng Q</pubmed_authors><pubmed_authors>Li A</pubmed_authors><pubmed_authors>Zhu X</pubmed_authors><pubmed_authors>Wang G</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Wang H</pubmed_authors><pubmed_authors>Xiao C</pubmed_authors><pubmed_authors>Zhou J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Esketamine vs Midazolam in Boosting the Efficacy of Oral Antidepressants for Major Depressive Disorder: A Pilot Randomized Clinical Trial.</name><description>&lt;h4>Importance&lt;/h4>Loss of a previously effective response while still using adequate antidepressant treatment occurs in a relatively high proportion of patients with major depressive disorder (MDD); therefore, there is a need to develop novel effective treatment strategies.&lt;h4>Objective&lt;/h4>To assess the efficacy and safety of a single subanesthetic dose of esketamine in boosting the efficacy of oral antidepressants for treating fluctuating antidepressant response in MDD.&lt;h4>Design, setting, and participants&lt;/h4>This single-center, double-blind, midazolam-controlled pilot randomized clinical trial was conducted at Beijing Anding Hospital, Capital Medical University in China. The study enrolled participants aged 18 years and older with fluctuating antidepressant response, defined as patien</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Aug</publication><modification>2025-04-04T09:24:41.178Z</modification><creation>2025-04-04T09:24:41.178Z</creation></dates><accession>S-EPMC10425830</accession><cross_references><pubmed>37578792</pubmed><doi>10.1001/jamanetworkopen.2023.28817</doi></cross_references></HashMap>